Pomeranz, Joanne

Pomeranz, Joanne was paid $117K by Medicaid between Jan 2019 and Jan 2021, across 6 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 51% of everything it billed.

33Billing provider infoPOMERANZ, JOANNE
HOLLIS, NH 03049

33aNPI1952566507assigned 07/23/2008

33bProvider typeFamily Nurse Practitioner

28Total paid$117K

24GClaims1,969

24DCodes billed6

24AFirst – last monthJan 2019 – Jan 2021

Compared with peers

Next to other Family Nurse Practitioner providers in New Hampshire

Rank by total paid#6 of 46

Median peer was paid$4K

This provider vs. median27×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	645	$37K
2020	1,304	$79K
2021	20	$808.35

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	51%	744	452	$60K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	31%	821	545	$36K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	9.9%	215	169	$12K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	8.0%	149	136	$9K
98966		<1%	23	18	$247.71
99406		<1%	17	14	$164.40

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.